←
Natera2,897 posts
Natera avatar✓

Natera ✓

@NateraGenetics

We’re on a mission to transform the management of disease worldwide.

◷ Joined September 2013▧ 1,020 Photos and videos
Natera avatar
Natera@NateraGenetics·Mar 31

This video reflects on the progress we’ve made, with a gracious nod to what comes next at Natera. It brings together different perspectives, from how the outside world sees our work, to the voices of patients and families sharing what this experience looks like in their own words. It also reflects the work happening behind the scenes across teams and disciplines. Most of us know someone impacted by cancer, planning for a baby, or navigating life after a transplant. It’s something we think about every day, and we’re honored to support people through some of life’s most important moments. We’re proud of the progress. Grateful for the trust patients place in us. And clear on how much more there is to do. If you have a few minutes, it’s worth a watch.

4:28
Natera avatar
Natera@NateraGenetics·19h

Exciting news! Natera has been named the Best in Class winner in the Cancer, Screening & Early Detection category at the The Digital Health Hub Foundation - Digital Health & AI Awards, announced live at #HLTHUSA 2026 in Las Vegas. This year’s competition drew more than 1,300 submissions worldwide, recognizing innovations advancing healthcare across multiple categories. The Cancer, Screening & Early Detection category was introduced for the first time this year, reflecting the growing role of digital and data-driven tools in the cancer continuum. James Stover, PhD, General Manager, Health Systems, Natera, accepted the award on behalf of Natera at the event. We're honored by this recognition, and grateful to the patients, clinicians, researchers, and partners who make this work possible. Read the full announcement: ow.ly/r7FX5107ptf @HLTHEVENT @DigiHlthHubFdn

Post attachment
Natera avatar
Natera@NateraGenetics·Nov 12

We’re partnering with @Incyte on a new interventional phase II study in early stage colorectal cancer (CRC), designed to treat patients at high risk of recurrence before disease appears on imaging. The trial will evaluate INCA33890, Incyte’s investigational bispecific immunotherapy, in patients with stage 2/3 CRC who have completed surgery and adjuvant chemotherapy (ACT). Following ACT, patients will undergo longitudinal testing with our Signatera™ MRD test for up to 12 months. Those who test MRD-positive and have no evidence of radiographic disease may be eligible for treatment. Thank you to our collaborators at Incyte for their vision and partnership. Read the full press release: ow.ly/NPfI5106b2f

Natera avatar
Natera@NateraGenetics·Nov 12

Happy Genetic Counselor Appreciation Day! Today, we celebrate genetic counselors everywhere: the clinicians, researchers, educators, innovators, and leaders who bring science and compassion together. To the more than 150 genetic counselors at Natera: thank you for guiding patients and families through some of life’s biggest moments. Your expertise and care are at the heart of everything we do. #GeneticCounselorAppreciationDay

0:06
Natera avatar
Natera@NateraGenetics·Nov 11

We honor and thank all who have served in the U.S. Armed Forces. We’re especially grateful to the veterans and military families who are part of the Natera community. Your service, dedication, and perspective strengthen our mission and inspire us every day. On Veterans Day, we’re sharing experiences from veterans at Natera. See what members of our veterans- and military family-focused employee resource group, Honor Bound, shared about their service and what it means to them today. #VeteransDay

Post attachmentPost attachmentPost attachmentPost attachment
Natera avatar
Natera@NateraGenetics·Nov 10

Hello from #NSGC26! See you at booth #1263 for resume reviews for #GeneticCounselors, prizes, information about Empower™ for hereditary cancer testing, and Zenith™ genomic testing for rare disease. See below for full details!

Post attachmentPost attachment
Natera avatar
Natera@NateraGenetics·Nov 10

Join Matt Love, VP, Business Development, RWD and AI, Natera, and Jacob Lalezari, MD, Head of Research & Translational Sciences, CytoDyn, for an open discussion on Natera and CytoDyn's ctDNA-MRD collaboration. Learn how MIIRA™, Natera's multi-timepoint molecular real-world data (RWD) platform is helping to inform decisions for CytoDyn's CLOVER Phase 2 study in metastatic colorectal cancer (mCRC) and supporting their broader drug development strategies. Register here: ow.ly/Sfvw5105AQ7

Natera avatar
Natera@NateraGenetics·Nov 10

After decades working in oncology, Shelly Glenn became a patient herself. In her story with Patient Worthy, she shares how she uses Signatera™ every three months to monitor her health in survivorship, and why advocating for yourself matters. 💙Thank you, Shelly, for sharing your voice and for inspiring others. Read her story: ow.ly/UGb05105y2W

Natera avatar
Natera@NateraGenetics·Nov 9

Natera team members recently attended the ASRM 2026 Scientific Congress & Expo in Baltimore, and the AASLD 2026 Liver Meeting in Denver. Thank you to the clinicians, colleagues, and partners who stopped by our booths, saw our presentations, and engaged in conversations about how our cell-free DNA tests can help inform more personalized health care decisions. #ASRM2026 #TLM26

Post attachmentPost attachment
Natera avatar
Natera@NateraGenetics·Nov 6

Join us for a practical, APP-led discussion on integrating Prospera™ Heart with DQS testing into transplant care. Register here: ow.ly/P31J5104Iy7 • Explore how two different transplant centers define the role of an APP in this evolving world of post-transplant care. • Discover the benefits of integrating Prospera into the post-transplant workflow. • Discuss real-world cases where a non-invasive alternative to surveillance biopsy can help drive clinical decisions. Whether you're considering using dd-cfDNA testing or looking to strengthen how it's used in your center, you'll leave with actionable insights on how to integrate Prospera into practice.

Post attachment
Matthew Rabinowitz avatar
⟳ Natera retweeted
Matthew Rabinowitz@MattRVerse·Nov 5

I’m grateful to Steve Chapman for his excellent leadership as Natera’s CEO, and excited to welcome Solomon Moshkevich as the company’s next CEO. 15 years at Natera, deep integrity and a true competitive spirit. The next chapter is in exceptional hands. natera.com/company/news/nate…

Natera avatar
Natera@NateraGenetics·Nov 5

Today we announced that Solomon Moshkevich has been appointed Chief Executive Officer of Natera. Solomon is a 15-year veteran of Natera and has been an instrumental leader driving our growth in women’s health and our rapid expansions into organ health and oncology. We’re deeply grateful to Steve Chapman, who has served successfully as Natera’s CEO since 2019 and helped grow our company into a global leader in cell-free DNA testing and precision medicine. Steve will support a seamless transition as a consultant to the company and advisor to the board. Congratulations, Solomon, and thank you, Steve, for the years of excellent leadership and dedication to Natera. You can read more in this press release: ow.ly/uRqO5104j0H @SMoshkevich

Natera avatar
Natera@NateraGenetics·Nov 4

Head and neck cancer can recur in up to 60% of patients, making early detection of recurrence critical. Signatera™ was recently featured in three new peer-reviewed publications in npj Precision Oncology, JAMA Otolaryngology, and Advances in Radiation Oncology. Collectively, the studies demonstrate Signatera’s ability to detect recurrence in advance of imaging and help predict which patients may benefit from adjuvant chemotherapy. These datasets build on the prospective Phase 2 SINERGY trial, which was selected for an oral plenary at the 2026 Multidisciplinary Head and Neck Cancers Symposium earlier this year. We’re proud to continue contributing important research that we hope will help patients with this type of cancer. Read more about these publications in our press release: ow.ly/Pb2n5103PYr

Natera avatar
Natera@NateraGenetics·Nov 3

Medicare coverage for Signatera™ just expanded to the most common type of liver cancer. Signatera has met coverage requirements from the CMS MolDX program in hepatocellular carcinoma (HCC). The coverage includes serial testing in the surveillance setting for patients with early-stage HCC who have no post-surgical evidence of disease. We’re pleased to share this news as clinical evidence continues to grow. Read the full press release: ow.ly/EgmJ5103lnO

Post attachment
Natera avatar
Natera@NateraGenetics·Nov 2

Join our upcoming webinar, Democratizing precision neurology: Expanding first-line genome access for every child in need. Tuesday, November 17, 2026 12:00 PM ET | 9:00 AM PT Register here: ow.ly/ElH85103ao8 During this session, our speakers will: • Examine the clinical justification for adopting broad genomic sequencing as an initial diagnostic tool • Explore which patient phenotypes may benefit most • Discuss the importance of expanding access to testing to help reduce diagnostic disparities • Demonstrate how a “one-test” strategy can provide clinicians with insights to guide personalized management earlier in a child’s care journey

Post attachment